Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Pfizer’s former CEO Ian Read and former CFO Frank D’Amelio now back the pharma, despite originally siding with Starboard.

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.